DK2121944T3 - In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser - Google Patents
In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelserInfo
- Publication number
- DK2121944T3 DK2121944T3 DK08707977.8T DK08707977T DK2121944T3 DK 2121944 T3 DK2121944 T3 DK 2121944T3 DK 08707977 T DK08707977 T DK 08707977T DK 2121944 T3 DK2121944 T3 DK 2121944T3
- Authority
- DK
- Denmark
- Prior art keywords
- qpct
- treatment
- alzheimer
- disease
- related disorders
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 102100029846 Glutaminyl-peptide cyclotransferase Human genes 0.000 title 1
- 101000585315 Homo sapiens Glutaminyl-peptide cyclotransferase Proteins 0.000 title 1
- 238000012750 in vivo screening Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Animal Husbandry (AREA)
- Endocrinology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88564907P | 2007-01-19 | 2007-01-19 | |
PCT/EP2008/050532 WO2008087197A1 (en) | 2007-01-19 | 2008-01-18 | In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2121944T3 true DK2121944T3 (da) | 2011-10-31 |
Family
ID=39271322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08707977.8T DK2121944T3 (da) | 2007-01-19 | 2008-01-18 | In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser |
Country Status (13)
Country | Link |
---|---|
US (1) | US20080200567A1 (de) |
EP (2) | EP2395095A1 (de) |
JP (1) | JP2010516235A (de) |
AT (1) | ATE521711T1 (de) |
AU (1) | AU2008206936B2 (de) |
CA (1) | CA2675192A1 (de) |
DK (1) | DK2121944T3 (de) |
ES (1) | ES2372229T3 (de) |
HR (1) | HRP20110651T1 (de) |
NZ (1) | NZ578513A (de) |
SI (1) | SI2121944T1 (de) |
WO (1) | WO2008087197A1 (de) |
ZA (1) | ZA200904353B (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9277737B2 (en) | 2006-09-21 | 2016-03-08 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the QPCTL-gene |
EP2118101B1 (de) * | 2007-03-09 | 2012-09-26 | Probiodrug AG | Imidazo[1,5-a]pyridinderivate als inhibitoren von glutaminylcyclase |
EP2160389B1 (de) * | 2007-04-18 | 2014-03-12 | Probiodrug AG | Thioxochinazolinonderivate als inhibitoren von glutaminylcyclase |
EP2142514B1 (de) * | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thioharnstoffderivate als glutaminylcyclaseinhibitoren |
US8772508B2 (en) * | 2007-04-18 | 2014-07-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
JP5675343B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としての尿素誘導体 |
DK2160380T3 (da) * | 2007-04-18 | 2014-06-30 | Probiodrug Ag | Cyano-guanidin derivater som glutaminyl cyclase inhibitorer |
WO2008128987A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Novel inhibitors |
WO2008128984A1 (en) * | 2007-04-20 | 2008-10-30 | Probiodrug Ag | Aminopyrimidine derivatives as glutaminyl cyclase inhibitors |
CA2696934A1 (en) * | 2007-09-12 | 2010-02-16 | Probiodrug Ag | Transgenic mice |
JP2011511622A (ja) * | 2008-01-14 | 2011-04-14 | プロビオドルグ エージー | グルタミニルシクラーゼ遺伝子のノックアウト変異を有するマウスモデル |
US20100028918A1 (en) * | 2008-07-31 | 2010-02-04 | Probiodrug Ag | Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases |
US11219696B2 (en) * | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
US8409837B2 (en) | 2010-08-19 | 2013-04-02 | Probiodrug Ag | Crystal structure of glutaminyl cyclase |
JP2013541938A (ja) | 2010-09-02 | 2013-11-21 | プロビオドルグ エージー | アイソqc関連障害の治療のためのインビボスクリーニングモデル |
EP2635675B1 (de) | 2010-11-02 | 2016-01-06 | Probiodrug AG | Kristallstruktur einer isoglutaminylcyclase |
US20130052203A1 (en) | 2011-08-12 | 2013-02-28 | Probiodrug Ag | In vivo screening models for treatment of qc-related disorders |
PT2879719T (pt) | 2012-08-01 | 2018-10-08 | Ohio State Innovation Foundation | Administração intratecal do vírus adeno-associado 9 recombinante |
US20180318260A1 (en) * | 2015-11-04 | 2018-11-08 | The Scripps Research Institute | Compositions and methods for treating cystic fibrosis |
MC200185B1 (fr) | 2016-09-16 | 2017-10-04 | Coronal Audio | Dispositif et procédé de captation et traitement d'un champ acoustique tridimensionnel |
MC200186B1 (fr) | 2016-09-30 | 2017-10-18 | Coronal Encoding | Procédé de conversion, d'encodage stéréophonique, de décodage et de transcodage d'un signal audio tridimensionnel |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
EP0264166B1 (de) | 1986-04-09 | 1996-08-21 | Genzyme Corporation | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
JPH07132033A (ja) * | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
US6948038B2 (en) * | 2001-07-24 | 2005-09-20 | Microsoft Corporation | System and method for backing up and restoring data |
ZA200508439B (en) * | 2003-05-05 | 2007-03-28 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
DE202004021723U1 (de) * | 2003-05-05 | 2010-07-15 | Probiodrug Ag | Medizinische Verwendung von Hemmern von Glutaminyl- und Glutamatcyclasen |
EP1620082B9 (de) | 2003-05-05 | 2010-08-25 | Probiodrug AG | Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen |
ZA200603165B (en) * | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
EP1713780B1 (de) * | 2004-02-05 | 2012-01-18 | Probiodrug AG | Neue inhibitoren von glutaminylcyclase |
GB0704100D0 (en) | 2006-03-17 | 2007-04-11 | Vodafone Plc | Improvements in an ehspa architecture |
EA016584B1 (ru) * | 2006-09-21 | 2012-06-29 | Пробиодруг Аг | Новые гены, родственные гену глутаминилциклазы |
-
2008
- 2008-01-18 SI SI200830434T patent/SI2121944T1/sl unknown
- 2008-01-18 JP JP2009545932A patent/JP2010516235A/ja active Pending
- 2008-01-18 NZ NZ578513A patent/NZ578513A/en not_active IP Right Cessation
- 2008-01-18 AU AU2008206936A patent/AU2008206936B2/en not_active Ceased
- 2008-01-18 ES ES08707977T patent/ES2372229T3/es active Active
- 2008-01-18 AT AT08707977T patent/ATE521711T1/de active
- 2008-01-18 EP EP11178419A patent/EP2395095A1/de not_active Withdrawn
- 2008-01-18 WO PCT/EP2008/050532 patent/WO2008087197A1/en active Application Filing
- 2008-01-18 EP EP08707977A patent/EP2121944B1/de not_active Not-in-force
- 2008-01-18 US US12/016,266 patent/US20080200567A1/en not_active Abandoned
- 2008-01-18 DK DK08707977.8T patent/DK2121944T3/da active
- 2008-01-18 CA CA002675192A patent/CA2675192A1/en not_active Abandoned
- 2008-01-18 ZA ZA200904353A patent/ZA200904353B/xx unknown
-
2011
- 2011-09-09 HR HR20110651T patent/HRP20110651T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
ATE521711T1 (de) | 2011-09-15 |
ES2372229T3 (es) | 2012-01-17 |
ZA200904353B (en) | 2010-09-29 |
CA2675192A1 (en) | 2008-07-24 |
NZ578513A (en) | 2012-01-12 |
AU2008206936A1 (en) | 2008-07-24 |
JP2010516235A (ja) | 2010-05-20 |
EP2121944B1 (de) | 2011-08-24 |
US20080200567A1 (en) | 2008-08-21 |
SI2121944T1 (sl) | 2011-12-30 |
HRP20110651T1 (hr) | 2011-10-31 |
AU2008206936B2 (en) | 2013-03-14 |
EP2121944A1 (de) | 2009-11-25 |
EP2395095A1 (de) | 2011-12-14 |
WO2008087197A1 (en) | 2008-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2121944T3 (da) | In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser | |
WO2009034158A3 (en) | Transgenic mice | |
CY1121252T1 (el) | Anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
HRP20190227T1 (hr) | Životinje koje nisu ljudi, koje imaju humanizirani gen za protein za reguliranje signala | |
CY2016029I1 (el) | Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9) | |
WO2008121199A3 (en) | Transgenic animal models of disease | |
PA8672101A1 (es) | Anticuerpos anti-il-6, composiciones, métodos y usos | |
UA111936C2 (uk) | ТРАНСГЕННА РОСЛИНА, ЯКА МІСТИТЬ ДНК, ЩО КОДУЄ ІНСЕКТИЦИДНИЙ БІЛОК Vip3Ab, І ДНК, ЩО КОДУЄ ІНСЕКТИЦИДНИЙ БІЛОК Cry1Ca, ДЛЯ КЕРУВАННЯ РЕЗИСТЕНТНІСТЮ КОМАХ | |
DE602004031881D1 (de) | Verfahren und materialien zur beurteilung von prostatakrebstherapien | |
NO20076563L (no) | Anti- MCP-1 antistoffer, sammensetninger og anvendelser | |
UA101301C2 (ru) | ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ | |
CR11434A (es) | Anticuerpos anti-amiloide humanos; composiciones, metodosy usos | |
EE200600039A (et) | Transgeenne loommudel patoloogilise ärevuse modelleerimiseks, meetod patoloogilisest ärevusest p?hjustatud haiguste v?i seisundite ravimiseks sobilike ühendite tuvastamiseks ja meetod Wfs1 valgu kasutamiseks sihtmärgina patoloogilise ärevuse vastase | |
ATE462787T1 (de) | Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington | |
DK2324126T3 (da) | FREMGANGSMÅDE TIL IDENTIFICERING AF Alzheimers SYGDOMSRISIKOFAKTORER | |
DK2276485T3 (da) | Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom | |
EA200900210A1 (ru) | Способ и набор для прогнозирования успеха имплантации при искусственном оплодотворении | |
ATE511348T1 (de) | Transgenes modell für morbus alzheimer | |
UA110774C2 (uk) | Нетрансгенна стійка до посухи рослина | |
WO2008153543A3 (en) | Fluorescent mouse model | |
ATE456797T1 (de) | Verwendung von nogo-c bei der beurteilung von herzversagen | |
ATE478707T1 (de) | Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen | |
WO2004062627A3 (en) | In vivo screening models for treatment of alzheimer's disease and other neurodegenerative disorders | |
WO2007135570A3 (en) | Pink1 deficient animals, screening methods, and related therapeutics | |
DE602004015622D1 (de) | Verfahren zur diagnose von fettleibigkeit |